These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 28859739)

  • 61. Interleukin-17 (IL-17) inhibitors in the treatment of plaque psoriasis: a review.
    Gooderham M; Posso-De Los Rios CJ; Rubio-Gomez GA; Papp K
    Skin Therapy Lett; 2015; 20(1):1-5. PubMed ID: 25807214
    [TBL] [Abstract][Full Text] [Related]  

  • 62. A safety evaluation of guselkumab for the treatment of psoriasis.
    Galluzzo M; D'Adamio S; Campione E; Bianchi L; Talamonti M
    Expert Opin Drug Saf; 2018 Jul; 17(7):741-751. PubMed ID: 29897790
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Use of biologic agents in pediatric psoriasis.
    Marji JS; Marcus R; Moennich J; Mackay-Wiggan J
    J Drugs Dermatol; 2010 Aug; 9(8):975-86. PubMed ID: 20684148
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Secukinumab re-initiation achieves regain of high response levels in patients who interrupt treatment for moderate to severe plaque psoriasis.
    Blauvelt A; Reich K; Warren RB; Szepietowski JC; Sigurgeirsson B; Tyring SK; Messina I; Bhosekar V; Oliver J; Papavassilis C; Frueh J; Langley RGB
    Br J Dermatol; 2017 Sep; 177(3):879-881. PubMed ID: 28498514
    [No Abstract]   [Full Text] [Related]  

  • 65. The status of biologic therapies in the treatment of moderate to severe psoriasis.
    Menter A
    Cutis; 2009 Oct; 84(4 Suppl):14-24. PubMed ID: 19916298
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Different response rates between palmoplantar involvement and diffuse plaque psoriasis in patients treated with infliximab.
    Brunasso AM; Puntoni M; Delfino C; Massone C
    Eur J Dermatol; 2012; 22(1):133-5. PubMed ID: 22134100
    [No Abstract]   [Full Text] [Related]  

  • 67. Practical understanding of mean percent psoriasis area and severity index reduction for biologics.
    English PL; Vender R
    J Cutan Med Surg; 2008; 12(6):282-7. PubMed ID: 19317950
    [TBL] [Abstract][Full Text] [Related]  

  • 68. A promising step forward in psoriasis therapy.
    Stern RS
    JAMA; 2003 Dec; 290(23):3133-5. PubMed ID: 14679277
    [No Abstract]   [Full Text] [Related]  

  • 69. Advances in psoriasis treatment.
    Schön MP
    Lancet; 2005 Oct 15-21; 366(9494):1333-5. PubMed ID: 16226595
    [No Abstract]   [Full Text] [Related]  

  • 70. Tildrakizumab (Ilumya) - another IL-23 antagonist for psoriasis.
    Med Lett Drugs Ther; 2019 Jan; 60(1563):4-6. PubMed ID: 30681661
    [No Abstract]   [Full Text] [Related]  

  • 71. A semi-mechanistic model to characterize the pharmacokinetics and pharmacodynamics of brodalumab in healthy volunteers and subjects with psoriasis in a first-in-human single ascending dose study.
    Salinger DH; Endres CJ; Martin DA; Gibbs MA
    Clin Pharmacol Drug Dev; 2014 Jul; 3(4):276-83. PubMed ID: 27128833
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Clinical experience of secukinumab in the treatment of erythrodermic psoriasis: a case series.
    Weng HJ; Wang TS; Tsai TF
    Br J Dermatol; 2018 Jun; 178(6):1439-1440. PubMed ID: 29265175
    [No Abstract]   [Full Text] [Related]  

  • 73. Anti-IL-17 Agents for Psoriasis: A Review of Phase III Data.
    Farahnik B; Beroukhim K; Nakamura M; Abrouk M; Zhu TH; Singh R; Lee K; Bhutani T; Koo J
    J Drugs Dermatol; 2016 Mar; 15(3):311-6. PubMed ID: 26954316
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Briakinumab versus Methotrexate for Psoriasis.
    Wu JJ
    N Engl J Med; 2012 Jan; 366(4):379-80; author reply 380. PubMed ID: 22276833
    [No Abstract]   [Full Text] [Related]  

  • 75. Briakinumab versus methotrexate for psoriasis.
    Malgarini RB; Pimpinella G
    N Engl J Med; 2012 Jan; 366(4):379; author reply 380. PubMed ID: 22276832
    [No Abstract]   [Full Text] [Related]  

  • 76. Suicidal thoughts end Amgen's blockbuster aspirations for psoriasis drug.
    Schmidt C
    Nat Biotechnol; 2015 Sep; 33(9):894-5. PubMed ID: 26348946
    [No Abstract]   [Full Text] [Related]  

  • 77. [Patient education. Information letter on treatment of psoriasis with infliximab (Remicade)].
    Groupe de recherche sur psoriasis de Société française de dermatologie, mai 2011
    Ann Dermatol Venereol; 2011 Dec; 138(12):865-7. PubMed ID: 22137633
    [No Abstract]   [Full Text] [Related]  

  • 78. Biologic therapy for psoriasis: the tumor necrosis factor inhibitors infliximab and etanercept.
    Weinberg JM; Saini R
    Cutis; 2003 Jan; 71(1):25-9. PubMed ID: 12553627
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Brodalumab: First Global Approval.
    Greig SL
    Drugs; 2016 Sep; 76(14):1403-12. PubMed ID: 27577550
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Safety of secukinumab in the treatment of psoriasis.
    Blauvelt A
    Expert Opin Drug Saf; 2016 Oct; 15(10):1413-20. PubMed ID: 27545070
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.